Survodutide versus placebo in adults with obesity or overweight and presumed or confirmed NASH

Phase 3, randomised, double-blind trial in metabolic dysfunction-associated steatohepatitis (MASH), obesity and Overweight comparing Survodutide with Placebo (2 arms). Primary endpoints: Relative reduction in liver fat content of at least 30% from baseline to Week 48 and Relative change in body weight from baseline to Week 48. Started Jun 2024; status: completed.